Filtered By:
Drug: Xolair
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 1700 results found since Jan 2013.
Characterization and pre-clinical assessment of a proposed biosimilar to its originator Omalizumab
Eur J Pharm Sci. 2022 Sep 8;178:106292. doi: 10.1016/j.ejps.2022.106292. Online ahead of print.ABSTRACTOmalizumab is an anti-IgE monoclonal antibody (mAb) approved for the treatment of moderate-to-severe asthma. Herein, we report physicochemical, biological, pharmacological, and toxicological characteristics of an Omalizumab biosimilar mAb named KA. We show that KA and its originator present only minimum differences. Their charge heterogeneity and primary, secondary structures are similar. The two molecules are comparable regarding in vitro activity, including molecular binding and cell-based inhibition. Pharmacological an...
Source: European Journal of Pharmaceutical Sciences - September 11, 2022 Category: Drugs & Pharmacology Authors: Yanchao Wang Chen Zheng Chao Zhuang Qiang Fu Baohong Zhang Yanling Bian Nianmin Qi Jianwei Zhu Source Type: research
The efficacy of omalizumab treatment in patients with nonatopic severe asthma
CONCLUSION: In the severe atopic asthma patient group, omalizumab treatment provided similar clinical benefits to those observed in patients with severe atopic asthma, suggesting that it may be a useful therapeutic option in patients with nonatopic asthma who failed to benefit from treatments with steps 4 and 5.PMID:36086957 | DOI:10.15586/aei.v50i5.594
Source: Allergologia et Immunopathologia - September 10, 2022 Category: Allergy & Immunology Authors: Emel Atayik Gokhan Aytekin Source Type: research
Corrigendum
With regard to the article in the May 2022 issue entitled “An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria” (J Allergy Clin Immunol 2022;149:1683-90.e7), the authors report an error in Fig 1, A. The authors regret that the levels of significance indicated on the omalizumab re fractory and ALL CSU patients should be switched. These levels of significance are defined as ∗P
Source: Journal of Allergy and Clinical Immunology - September 1, 2022 Category: Allergy & Immunology Tags: Corrigendum Source Type: research
Pathophysiology, Diagnosis, and Management of Chronic Spontaneous Urticaria: A Literature Review
AbstractChronic spontaneous urticaria (CSU) is characterized by recurring wheals that last 6 weeks or longer without an identifiable cause. The estimated point prevalence of CSU worldwide is 1%. Furthermore, it has a significant impact on quality of life in both adults and pediatric patients and their families. Although it is most often a self-limited disease, some patients have urticaria refractory to first-line treatment: second-generation H1 antihistamines. In these patients, the use of targeted monoclonal antibodies is necessary. While omalizumab is the only Food and Drug Administration-approved monoclonal antibody f...
Source: Clinical Reviews in Allergy and Immunology - September 1, 2022 Category: Allergy & Immunology Source Type: research
